Login / Signup

Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages.

Andrew LyKhaled SanberHua-Ling TsaiAngela OndoKathy MooneyAudra ShedeckJulie BakerPhilip Hollingsworth ImusNina D Wagner-JohnstonTania Jain
Published in: British journal of haematology (2023)
Keyphrases
  • cell therapy
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • stem cells
  • prognostic factors
  • mesenchymal stem cells
  • peritoneal dialysis
  • patient reported outcomes
  • patient reported